Corvus Pharma Com (CRVS)

$15.10 -0.57 (-3.64%)
Market Cap 1.32B
Revenue (ttm) 0.00
Net Income (ttm) -15.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 547,200
Avg Vol 1,337,238
Day's Range N/A - N/A
Shares Out 83.99M
Stochastic %K 69%
Beta 0.97
Analysts Strong Sell
Price Target $35.17

Company Profile

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hid...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 900 4520
Address:
901 Gateway Boulevard, Third Floor, South San Francisco, United States
MedicalDoctorInvestor
MedicalDoctorInvestor Apr. 11 at 7:58 PM
$CRVS Jelly’s future home
1 · Reply
tradingjunk321
tradingjunk321 Apr. 11 at 6:29 PM
$CRVS Just some Moore Saturday reading.
1 · Reply
DDtrader444
DDtrader444 Apr. 11 at 2:57 PM
$CRVS ↘️↘️↘️ delusional bulls😂
1 · Reply
lousjamsession
lousjamsession Apr. 11 at 4:40 AM
$CRVS
0 · Reply
Jellysquid1
Jellysquid1 Apr. 11 at 2:55 AM
$CRVS GOOD Comment Regarding Seeking Alpha’s DUM Crvs Written Article
2 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor Apr. 11 at 1:15 AM
$CRVS
1 · Reply
Jellysquid1
Jellysquid1 Apr. 10 at 10:55 PM
$CRVS To all you Bears I suggest you read ALL that Tradingjunk has Posted below, And you will see that Soquelitinib will become A Novel Mechanism in Cancers! Waiting for May to Hear more From Miller!
0 · Reply
tradingjunk321
tradingjunk321 Apr. 10 at 7:34 PM
$CRVS Much Moore! https://x.com/hothomaswphelps/status/2042683294655881356?s=42
1 · Reply
KingKai2020
KingKai2020 Apr. 10 at 5:19 PM
$CRVS money flows pivoted into tech/chips and bio flat to lower across the board. shorts of course doing their dirty deed of trying to unwind the gains of wed and thurs.....
1 · Reply
tradingjunk321
tradingjunk321 Apr. 10 at 4:35 PM
$CRVS Moore!
0 · Reply
Latest News on CRVS
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 12, 2026, 4:01 PM EDT - 4 weeks ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Mar 5, 2026, 4:01 PM EST - 5 weeks ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 4:01 PM EST - 6 weeks ago

Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Jan 23, 2026, 5:00 PM EST - 2 months ago

Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Jan 21, 2026, 10:53 PM EST - 2 months ago

Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 20, 2026, 4:01 PM EST - 2 months ago

Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

What made Corvus stock double on Tuesday and is it sustainable?

Jan 20, 2026, 2:10 PM EST - 2 months ago

What made Corvus stock double on Tuesday and is it sustainable?

Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Jan 20, 2026, 2:00 PM EST - 2 months ago

Corvus Stock Spikes On Heels Of Strong Eczema Study Results

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 16, 2026, 4:01 PM EST - 3 months ago

Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 4, 2025, 4:01 PM EST - 5 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Oct 31, 2025, 7:30 AM EDT - 5 months ago

Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Oct 28, 2025, 4:01 PM EDT - 5 months ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Oct 17, 2025, 10:00 AM EDT - 6 months ago

Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Oct 2, 2025, 4:01 PM EDT - 6 months ago

Corvus Pharmaceuticals Appoints David Moore to Board of Directors

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:01 PM EDT - 8 months ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jun 4, 2025, 7:00 AM EDT - 11 months ago

Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025, 4:01 PM EDT - 11 months ago

Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

May 9, 2025, 11:57 AM EDT - 1 year ago

Why Is Corvus Pharmaceuticals Stock Soaring On Friday?

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:02 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

May 8, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Apr 23, 2025, 4:08 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Apr 9, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 25, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 19, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Mar 17, 2025, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS)

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 4, 2025, 8:00 AM EST - 1 year ago

Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Jan 13, 2025, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Dec 18, 2024, 1:23 PM EST - 1 year ago

Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday?

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Dec 18, 2024, 8:42 AM EST - 1 year ago

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session

HEI TSLA

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Dec 18, 2024, 7:30 AM EST - 1 year ago

Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Dec 17, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Dec 4, 2024, 4:05 PM EST - 1 year ago

Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Nov 14, 2024, 10:01 AM EST - 1 year ago

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:01 PM EST - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Nov 9, 2024, 1:40 PM EST - 1 year ago

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Nov 5, 2024, 4:02 PM EST - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Sep 17, 2024, 8:00 AM EDT - 1 year ago

Kaskela Law LLC Announces Shareholder Investigation of Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) and Encourages Investors to Contact the Firm

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Sep 10, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Aug 6, 2024, 4:01 PM EDT - 1 year ago

Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

May 30, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

May 6, 2024, 4:01 PM EDT - 2 years ago

Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

May 2, 2024, 4:02 PM EDT - 2 years ago

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

May 2, 2024, 8:30 AM EDT - 2 years ago

Corvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct Offering

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Apr 9, 2024, 4:01 PM EDT - 2 years ago

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

MedicalDoctorInvestor
MedicalDoctorInvestor Apr. 11 at 7:58 PM
$CRVS Jelly’s future home
1 · Reply
tradingjunk321
tradingjunk321 Apr. 11 at 6:29 PM
$CRVS Just some Moore Saturday reading.
1 · Reply
DDtrader444
DDtrader444 Apr. 11 at 2:57 PM
$CRVS ↘️↘️↘️ delusional bulls😂
1 · Reply
lousjamsession
lousjamsession Apr. 11 at 4:40 AM
$CRVS
0 · Reply
Jellysquid1
Jellysquid1 Apr. 11 at 2:55 AM
$CRVS GOOD Comment Regarding Seeking Alpha’s DUM Crvs Written Article
2 · Reply
MedicalDoctorInvestor
MedicalDoctorInvestor Apr. 11 at 1:15 AM
$CRVS
1 · Reply
Jellysquid1
Jellysquid1 Apr. 10 at 10:55 PM
$CRVS To all you Bears I suggest you read ALL that Tradingjunk has Posted below, And you will see that Soquelitinib will become A Novel Mechanism in Cancers! Waiting for May to Hear more From Miller!
0 · Reply
tradingjunk321
tradingjunk321 Apr. 10 at 7:34 PM
$CRVS Much Moore! https://x.com/hothomaswphelps/status/2042683294655881356?s=42
1 · Reply
KingKai2020
KingKai2020 Apr. 10 at 5:19 PM
$CRVS money flows pivoted into tech/chips and bio flat to lower across the board. shorts of course doing their dirty deed of trying to unwind the gains of wed and thurs.....
1 · Reply
tradingjunk321
tradingjunk321 Apr. 10 at 4:35 PM
$CRVS Moore!
0 · Reply
ILikeDaStocks
ILikeDaStocks Apr. 10 at 4:13 PM
$CRVS Looow volume, but the shorts sure are enjoying the morning! Wish a few buyers would step in...
0 · Reply
dwsrph1
dwsrph1 Apr. 10 at 1:34 PM
$CRVS Since again we have to suffer through the weekend until Monday; how about 15% up today!! I’ll take 3%!!😁
1 · Reply
tradingjunk321
tradingjunk321 Apr. 10 at 12:14 PM
$CRVS as I said yesterday! Moore to come!
2 · Reply
lousjamsession
lousjamsession Apr. 10 at 4:24 AM
$CRVS .....
0 · Reply
DDtrader444
DDtrader444 Apr. 9 at 9:08 PM
$CRVS get ready jellybelly↘️↘️↘️
1 · Reply
tradingjunk321
tradingjunk321 Apr. 9 at 7:30 PM
$CRVS looks like we finally resumed an uptrend, especially going into Mays data
1 · Reply
Clearly_
Clearly_ Apr. 9 at 3:51 PM
$CRVS this was bought with stolen funds
1 · Reply
Clearly_
Clearly_ Apr. 9 at 3:50 PM
$CRVS criminal stock
1 · Reply
dwsrph1
dwsrph1 Apr. 9 at 3:46 PM
$CRVS
3 · Reply
dwsrph1
dwsrph1 Apr. 9 at 3:04 PM
$CRVS CDTX @cdtx 4h T cell platform company’s are becoming leading cancer research today CRVS immunity bio and PDSB are all platforms with incredible data across their differentiated platforms.
0 · Reply
dwsrph1
dwsrph1 Apr. 9 at 3:00 PM
$CRVS
0 · Reply
Jellysquid1
Jellysquid1 Apr. 9 at 1:48 PM
$CRVS New people Are Getting More interested in T Cell Platform Companies Especially CRVS!
0 · Reply